Paul Hughes, Ph.D.

Scientific Director at Amgen

Since joining Amgen in 2003 my research has been focused on the discovery of novel small and large molecule oncology therapeutics. My group contributed to the discovery of AMG 757, a first-in-class DLL3-targeted bispecific T-cell engager molecule BITE molecule targeting DLL3. I’m currently actively engaged in cross-functional teams to develop novel targeted therapies focused on drugging proteins that are genetically altered in cancer.